Indaptus Therapeutics Reports Critical Cash Shortage, Less Than One Month of Operating Funds Remaining
INDP sits 16% above its 52-week low of $1.51 on light trading volume (0.1× avg).
Summary
Indaptus Therapeutics disclosed a critically low cash balance of $1.5 million, with a burn rate of $7.0 million per quarter, indicating less than one month of operating funds remaining and an urgent need for new capital.
Key Events · Financing and Capital Events · INDP
-
Critically Low Cash Position
Cash and cash equivalents plummeted to $1.5 million as of March 31, 2026, down from $8.5 million at the end of 2025.
-
Rapid Cash Burn
The company used $7.0 million in cash from operating activities during Q1 2026, implying a burn rate that far exceeds its current cash reserves.
-
Urgent Need for Capital
Management explicitly stated the company needs to raise additional capital to continue operations, with no assurance that financing will be available on acceptable terms or at all.
-
Reiteration of Going Concern
The filing reinforces the substantial doubt about the company's ability to continue as a going concern, a warning previously issued in its 10-K.
Analysis · INDP · Life Sciences
Indaptus Therapeutics has reported a critically low cash balance of $1.5 million as of March 31, 2026, while burning $7.0 million in cash from operations during the first quarter. This indicates the company has less than one month of operating funds remaining, exacerbating the previously disclosed going concern warning. The company explicitly states it needs to raise additional capital but cannot assure its availability, putting its future operations in severe jeopardy.
At the time of this filing, INDP was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.51 to $19.91. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.